pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
the cabinet

Drugs

6,918 products tracked · 1,831 matching

★ save view↓export CSV
phase
allMarketedPhase 3Phase 2Phase 1Preclinical
sort
catalystsrecentname
therapeutic area
allOncology1831Infectious Disease718Cardiology425Pulmonology396Immunology371Ophthalmology368Dermatology300Women's Health
viewlistcards
Marketed
selinexor
Xpovio (selinexor)
Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)
Exportin-1
$KPTIKaryopharm Therapeutics Inc.
7 catalysts
Marketed
imlunestrant tosylate
Inluriyo (imlunestrant tosylate)
Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast…
Eli Lilly and Co
1 catalysts
Marketed
paltusotine hydrochloride
Palsonify (paltusotine hydrochloride)
Carcinoid Syndrome (Malignant Carcinoid Syndrome)
Crinetics Pharmaceuticals, Inc.
← prev
page 6 of 62
next →
131
Pain89
Neurology1
$CRNX
1 catalysts
Marketed
triptorelin pamoate ER
Triptodur (triptorelin pamoate)
Central Precocious Puberty
Azurity Pharmaceuticals Inc
64 catalysts
Marketed
LEUPROLIDE ACETATE
LEUPROLIDE ACETATE (LEUPROLIDE ACETATE)
Gonadotropin-releasing hormone receptor
$AMRXAmneal Pharmaceuticals, Inc.
37 catalysts
Phase 2
(atigotatug + nivolumab)
(atigotatug [INN] + nivolumab)
Small-Cell Lung Cancer
Bristol-Myers Squibb Co
0 catalysts
Phase 3
(azacitidine + cedazuridine)
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Taiho Oncology Inc
0 catalysts
Marketed
(betamethasone acetate + betamethasone sodium phosphate)
Celestone Soluspan ((betamethasone acetate + betamethasone sodium phosphate))
Cerebral Edema
$OGNOrganon & Co.
0 catalysts
Preclinical
(calcipotriene + fluorouracil)
Cutaneous Squamous Cell Carcinoma (cSCC)
Phd Skin Care LLC
0 catalysts
Preclinical
(cannabidivarin + cannabigerolic acid)
Colorectal Cancer
$CNBXCNBX Pharmaceuticals Inc.
0 catalysts
Marketed
(cedazuridine + decitabine)
Inqovi ((cedazuridine + decitabine))
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Otsuka Pharmaceutical Co Ltd
0 catalysts
Phase 3
(cisplatin + vinblastine sulphate)
Dedifferentiated Liposarcoma
$INTSINTENSITY THERAPEUTICS, INC.
0 catalysts
Marketed
(cytarabine hydrochloride + daunorubicin hydrochloride)
Vyxeos ((cytarabine hydrochloride + daunorubicin hydrochloride))
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
$JAZZJazz Pharmaceuticals plc
0 catalysts
Phase 2
(docetaxel + gemcitabine) SR
(docetaxel + gemcitabine)
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
$RLMDRELMADA THERAPEUTICS, INC.
0 catalysts
Preclinical
(gemcitabine + paclitaxel)
(gemcitabine+ paclitaxel)
Pancreatic Ductal Adenocarcinoma
Duo Oncology Inc
0 catalysts
Marketed
(hyaluronidase (recombinant human) + pertuzumab + trastuzumab)
Phesgo ((hyaluronidase-zzxf (recombinant human) + pertuzumab + trastuzumab))
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast…
Genentech Inc
0 catalysts
Marketed
(hyaluronidase (recombinant, human) + rituximab)
Rituxan Hycela ((hyaluronidase (recombinant, human) + rituximab))
Chronic Lymphocytic Leukemia (CLL)
Genentech Inc
0 catalysts
Marketed
(hyaluronidase (recombinant, human) + trastuzumab)
Herceptin Hylecta ((hyaluronidase-oysk (recombinant, human) + trastuzumab))
Breast Cancer
Genentech Inc
0 catalysts
Phase 2
(nanatinostat + valganciclovir)
(nanatinostat + valganciclovir [INN])
Post-Transplant Lymphoproliferative Disorder
Viracta Therapeutics Inc
0 catalysts
Marketed
(nivolumab + relatlimab)
Opdualag ((nivolumab + relatlimab-rmbw))
Metastatic Melanoma
Bristol-Myers Squibb Co
0 catalysts
Phase 2
(prednisone + valproate sodium)
(prednisone [INN] + valproate sodium)
Diffuse Large B-Cell Lymphoma
Respiratorius AB
0 catalysts
Phase 2
(senaparib + temozolomide)
(senaparib [INN] + temozolomide)
Small-Cell Lung Cancer
IMPACT Therapeutics Inc
0 catalysts
Marketed
(tipiracil hydrochloride + trifluridine)
Lonsurf ((tipiracil hydrochloride + trifluridine))
Adenocarcinoma Of The Gastroesophageal Junction
Taiho Oncology Inc
0 catalysts
Preclinical
15d-PMJ2
Colon Cancer
Claradele Pharmaceuticals Inc
0 catalysts
Phase 2
177Lu-LNC-1011
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Yantai Lannacheng Biotechnology Co Ltd
0 catalysts
Preclinical
188-RNLBAM
Hepatocellular Carcinoma
$PSTVPLUS THERAPEUTICS, INC.
0 catalysts
Phase 1
212Pb-GRPR
Cervical Cancer
Orano Med LLC
0 catalysts
Preclinical
212Pb-LNC-1011
Prostate Cancer
Yantai Lannacheng Biotechnology Co Ltd
0 catalysts
Preclinical
3D-059
Unspecified Cancer
$SLSSELLAS Life Sciences Group, Inc.
0 catalysts
Preclinical
3D-062
Unspecified Cancer
3D Medicines Inc
0 catalysts